Abbott Parenteral Manufacturing Is Subject Of FDA Warning Letter
Executive Summary
Abbott's discussions with FDA over the good manufacturing practices compliance of its in vitro diagnostics business also included discussions of the GMP status of its large- and small-volume parenteral drug manufacturing operations.
You may also be interested in...
FDA Systems-Based Inspection Approach To Be Expanded By Early 2002
FDA's systems-based inspection program could be expanded nationwide at the beginning of 2002, CDER Office of Compliance Division of Manufacturing & Product Quality Director Joseph Famulare told the Regulatory Affairs Professionals Society meeting in Baltimore, Md. Nov. 6
FDA Systems-Based Inspection Approach To Be Expanded By Early 2002
FDA's systems-based inspection program could be expanded nationwide at the beginning of 2002, CDER Office of Compliance Division of Manufacturing & Product Quality Director Joseph Famulare told the Regulatory Affairs Professionals Society meeting in Baltimore, Md. Nov. 6
Abbott warning letter
Company's North Chicago, Ill., plant receives warning letter citing sterilization validation problems in production of Abbott's acute porphyria therapy Panhematin (hemin for injection), following FDA inspection in March. The July letter comes one year after Abbott's parenteral manufacturing plant in North Chicago received a warning letter relating to GMP deviations in its aseptic manufacturing process (1"The Pink Sheet" Nov. 29, 1999, p. 28). Abbott's diagnostic division is operating under a GMP consent agreement signed in November 1999